Navigation Links
Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury

NEW BRUNSWICK, N.J. Rutgers University and Massachusetts General Hospital (MGH) investigators have developed a novel strategy to protect the liver from drug-induced injury and improve associated drug safety.

In a report receiving advance online publication in the journal Nature Biotechnology, the team reports that inhibiting a type of cell-to-cell communication can protect against damage caused by liver-toxic drugs such as acetaminophen.

"Our findings suggest that this therapy could be a clinically viable strategy for treating patients with drug-induced liver injury," said Suraj Patel a postdoctoral researcher in the Center for Engineering in Medicine at MGH and the paper's lead author. "This work also has the potential to change the way drugs are developed and formulated, which could improve drug safety by providing medications with reduced risk of liver toxicity."

Drug-induced liver injury is the most common cause of acute liver failure in the U.S. and is also the most frequent reason for abandoning drugs early in development or withdrawing them from the market. Liver toxicity limits the development of many therapeutic compounds and presents major challenges to both clinical medicine and to the pharmaceutical industry.

Since no pharmaceutical strategies currently exist for preventing drug-induced liver injury, treatment options are limited to discontinuing the offending drug, supportive care and transplantation for end-stage liver failure.

The researchers investigated an approach that targets a liver's gap junctions hollow multimolecular channels that connect neighboring cells and allow direct communication between coupled cells. In the heart, gap junctions propagate the electrical activity required for synchronized contraction, but their role in the liver has not been well understood

Recent work has shown that gap junctions spread immune signals from injured liver cells to surrounding undamaged cells, amplifying inflammation and injury. The current study examined inhibiting the action of liver-specific gap junctions to limit drug-induced liver injury.

The researchers first used a strain of genetically mutated mice that lack a particular liver-specific gap junction. The mice were administered various liver-toxic drugs such as acetaminophen, a commonly used medication best known under the Tylenol brand name. Acetaminophen overdoses are the most frequent cause of drug-induced liver injury.

Compared to normal mice, those lacking liver gap junctions were fully protected against liver damage, inflammation and death caused by administration of liver-toxic drugs. The team then identified a small-molecule inhibitor of liver gap junctions that, when given with or even after the toxic drugs, protected the livers of normal mice against injury and prevented their death.

"This finding is very exciting and potentially very powerful from a number of basic science and clinical application standpoints, which we are continuing to explore," said Martin Yarmush, senior author of the report and the Paul and Mary Monroe Professor of Biomedical Engineering at Rutgers. "However, before we can think about applying this approach to patients, we need to know more about any off-target effects of gap junction inhibitors and better understand the long-term ramifications of temporarily blocking liver-specific gap junction channels."

Additionally, cell culture experiments indicated that blocking gap junctions limited the spread through liver cells of damaging free radicals and oxidative stress, suggesting a possible mechanism for the observed protection.

Contact: Carl Blesch
732-932-7084 x616
Rutgers University

Related medicine news :

1. Even privately insured have hard time getting psychiatric care in Massachusetts: Harvard study
2. Massachusetts health-care reform increased access to care, particularly among disadvantaged
3. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
4. Study examines impact of Massachusetts health law on emergency department visits
5. Support for Massachusetts landmark health reform law rises in 2011
6. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
7. Season of birth and celiac disease in Massachusetts children
8. Massachusetts reform hasnt stopped medical bankruptcies: Harvard study
9. Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
10. Massachusetts physician groups improving patient experience, study finds
11. Massachusetts Institute of Technology IDs new cancer drug target
Post Your Comments:
Related Image:
Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: AGN ) ... New York State Attorney General,s Office ... Act, and other statutes with the Attorney General over the ... cease marketing and selling the now generic version of memantine ... no liability, has released its counterclaims against New ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... - Will Also Offer Point -of- ... --> - Will Also Offer Point ... --> - Will Also Offer ... (CME) Elsevier , a world-leading provider of ... diagnostic imaging textbooks and decision support tools, as well as prominent ...
Breaking Medicine Technology: